Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.
2.

Bisphophonates in CKD patients with low bone mineral density.

Liu WC, Yen JF, Lang CL, Yan MT, Lu KC.

ScientificWorldJournal. 2013 Dec 31;2013:837573. doi: 10.1155/2013/837573. eCollection 2013. Review.

3.

Diagnosis and treatment of osteoporosis in chronic renal disease.

Miller PD.

Semin Nephrol. 2009 Mar;29(2):144-55. doi: 10.1016/j.semnephrol.2009.01.007. Review.

PMID:
19371805
4.

Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.

McCarley PB, Arjomand M.

Nephrol Nurs J. 2008 Jan-Feb;35(1):59-64. Review.

PMID:
18372764
5.

Can bisphosphonates play a role in the treatment of children with chronic kidney disease?

Haffner D, Fischer DC.

Pediatr Nephrol. 2011 Dec;26(12):2111-9. doi: 10.1007/s00467-010-1739-z. Epub 2011 Jan 27. Review.

PMID:
21267600
6.

[Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].

Goto S, Fukagawa M.

Clin Calcium. 2007 Dec;17(12):1830-4. Review. Japanese.

PMID:
18057657
7.

Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.

Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H.

Ren Fail. 2008;30(4):407-10. doi: 10.1080/08860220801964210.

PMID:
18569914
8.

[Chronic arthralgia in a 46-year-old patient with renal failure].

Schiller B, Hillebrand G, Bartl R, Linke RP.

Internist (Berl). 1992 Feb;33(2):117-21. German. No abstract available.

PMID:
1568827
9.

Caring for chronic kidney disease patients: focus on mineral and bone disorders.

Nguyen TV, Filson J.

Consult Pharm. 2009 Feb;24(2):146-52.

PMID:
19275456
10.

Renal osteodystrophy.

Haas M.

Wien Med Wochenschr. 2004;154(5-6):107-18. Review.

PMID:
15106893
11.
12.

Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series.

Amerling R, Harbord NB, Pullman J, Feinfeld DA.

Blood Purif. 2010;29(3):293-9. doi: 10.1159/000276666. Epub 2010 Jan 21.

PMID:
20090316
13.

[Kidney and bone update : the 5-year history and future of CKD-MBD. Bone fragility in the aged hemodialysis patients].

Imanishi Y.

Clin Calcium. 2012 Jul;22(7):1025-33. doi: CliCa120710251033. Review. Japanese.

PMID:
22750935
14.

An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism.

Malluche HH, Monier-Faugere MC, Wang G, Fraz√£ O JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG.

Clin Nephrol. 2008 Apr;69(4):269-78.

PMID:
18397701
15.

Therapy for patients with CKD and low bone mineral density.

Ott SM.

Nat Rev Nephrol. 2013 Nov;9(11):681-92. doi: 10.1038/nrneph.2013.182. Epub 2013 Oct 8. Review.

PMID:
24100401
16.

A structural approach to renal bone disease.

Parfitt AM.

J Bone Miner Res. 1998 Aug;13(8):1213-20. Review. No abstract available.

17.
18.

[Mineral and bone disorders associated with chronic kidney disease].

Arboleya L.

Reumatol Clin. 2011 Sep;7 Suppl 2:S18-21. doi: 10.1016/j.reuma.2011.05.006. Epub 2011 Aug 3. Review. Spanish.

19.

The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.

Li D, Shao L, Zhou H, Jiang W, Zhang W, Xu Y.

Endocrine. 2013 Feb;43(1):68-77. doi: 10.1007/s12020-012-9711-2. Epub 2012 Jun 6.

PMID:
22669774
20.

Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.

Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G.

J Nephrol. 2006 Sep-Oct;19(5):566-77. Review.

PMID:
17136683
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk